Skip to main content

Table 4 Association between M-, T- and C- scores and clinical outcome in STOP-IgAN patients (available cases analysis)

From: Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores)

  M0 events/ total M1 events/ total p-value T0 events/ total T1/2 events/ total p-value C0 events/ total C1/2 events/ total p-value
Full clinical remissiona 8/48 (17%) 0/17 (0%) 0.099 6/39 (15%) 2/26 (8%) 0.460 4/45 (9%) 4/20 (20%) 0.238
GFR-loss ≥15 ml/min 14/51 (27%) 9/18 (50%) 0.092 11/40 (28%) 12/29 (41%) 0.302 16/47 (34%) 7/22 (32%) 1.000
ESRDb 7/51 (14%) 1/18 (6%) 0.671 1/40 (3%) 7/29 (24%) 0.008 4/47 (9%) 4/22 (18%) 0.255
Disappearance of microhematuria 11/34 (32%) 3/15 (20%) n.d. c 10/29 (35%) 4/20 (20%) n.d. c 10/34 (29%) 4/15 (27%) 1.000
Absolute annual GFR change (ml/min/1.73m2) −0.79 ± 4.50 −5.06 ± 5.17 0.002 −2.05 ± 5.40 −2.01 ± 4.54 0.362 − 2.66 ± 5.02 −0.82 ± 5.02 0.131
  1. aurinary protein-creatinine ratio < 0.2 g/g and an eGFR decrease of < 5 ml/min/1.73m2
  2. bend-stage renal disease
  3. cnot determined (due to the low total numbers of available data points in this category, n = 49)